HomeHealthcare & Life SciencesPharmaceuticals Hepatic Encephalopathy Treatment Market

Australia Hepatic Encephalopathy Treatment Market Size & Outlook, 2026-2034


Australia Hepatic Encephalopathy Treatment Market Insights

  • Based on Reed Intelligence findings, the Australia Hepatic Encephalopathy Treatment Market reached USD 22.13 Million in 2025 and is estimated to attain USD 44.11 Million by 2034.
  • From 2026 to 2034, the Australia market is expected to grow at a steady CAGR of 7.92%.
  • Within the Drug Class category, Rifaximin dominated in 2025 in terms of market size contribution.
  • Over the forecast period, Microbiome-based Therapies is forecasted to deliver the fastest growth, positioning it as the most lucrative Drug Class segment.

Other Key Findings


  • In 2025, Australia accounted for 0.89% of the global Hepatic Encephalopathy Treatment Market size.
  • By 2034, United States is expected to lead the global Hepatic Encephalopathy Treatment Market in terms of market size.
  • Within Asia Pacific, China is projected to dominate the regional Hepatic Encephalopathy Treatment Market size by 2034.
  • Japan is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 102.85 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 22.13 Million
Market Size In 2034 USD 44.11 Million
Largest segment Rifaximin
Units Revenue in USD Million
CAGR 7.92% (2026-2034)
Segmnetation Covered
Drug Class
  1. Rifaximin
  2. Lactulose
  3. L-ornithine L-aspartate
  4. Antibiotics
  5. Microbiome-based Therapies
Disease Type
  1. Overt Hepatic Encephalopathy
  2. Minimal Hepatic Encephalopathy
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports